2018
Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study
Oldham MA, Hawkins KA, Lin IH, Deng Y, Hao Q, Scoutt LM, Yuh DD, Lee HB. Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study. American Journal Of Geriatric Psychiatry 2018, 27: 476-486. PMID: 30709616, PMCID: PMC6443412, DOI: 10.1016/j.jagp.2018.12.025.Peer-Reviewed Original ResearchConceptsMiddle cerebral arteryMild cognitive impairmentCerebrovascular diseaseCognitive impairmentRisk factorsCoronary artery bypass graft surgeryStenosis severityProspective observational cohort studyArtery bypass graft surgeryBilateral middle cerebral arteriesTertiary care academic hospitalHeart Surgery studyPreoperative cognitive assessmentUndergoing CABG surgeryBypass graft surgeryConfusion Assessment MethodRisk of deliriumDelirium risk factorsObservational cohort studyPostoperative day 2Clinical Dementia RatingDepression InterviewPreoperative depressionStructured HamiltonStudy psychiatrist
2015
Cognitive and functional status predictors of delirium and delirium severity after coronary artery bypass graft surgery: an interim analysis of the Neuropsychiatric Outcomes After Heart Surgery study
Oldham MA, Hawkins KA, Yuh DD, Dewar ML, Darr UM, Lysyy T, Lee HB. Cognitive and functional status predictors of delirium and delirium severity after coronary artery bypass graft surgery: an interim analysis of the Neuropsychiatric Outcomes After Heart Surgery study. International Psychogeriatrics 2015, 27: 1929-1938. PMID: 26423721, PMCID: PMC9310349, DOI: 10.1017/s1041610215001477.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentHeart Surgery studyConfusion Assessment MethodPost-operative deliriumDelirium severityLawton IADL scoresIADL scoresNeuropsychiatric outcomesDelirium IndexSurgery StudyCoronary artery bypass graft surgeryArtery bypass graft surgeryPost-operative day 2Clinical Dementia Rating ScaleMCI-NCElective CABG surgeryBypass graft surgeryObservational cohort studyDementia Rating ScaleCABG surgeryGraft surgeryCohort studyFunctional statusFunctional impairmentCDR sumCognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings
Chahine M, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Movement Disorders 2015, 31: 86-94. PMID: 26293177, PMCID: PMC4827252, DOI: 10.1002/mds.26373.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnxietyAttentionCocaineCognition DisordersCohort StudiesExecutive FunctionFemaleHumansLanguageMaleMemoryMiddle AgedNeurogenic BowelNeuropsychological TestsOlfaction DisordersParkinson DiseaseProtein BindingRadiopharmaceuticalsSelf ReportSeverity of Illness IndexStatistics, NonparametricSurveys and QuestionnairesTomography, Emission-Computed, Single-PhotonVisual PerceptionConceptsExecutive function/Global cognitionRelative impairmentSpecific cognitive domainsSpeed/attentionGlobal cognitive abilityNeuropsychological test batteryLower global cognitionFunction/Cognitive abilitiesCognitive domainsCognitive profileVisuospatial abilitiesLanguage domainsCognitive testingTest batteryCognitionNormative scoresMemoryLower mean scoresHealthy adultsNon-motor featuresIndividualsStudy findingsNon-motor symptomsCognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors
2010
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients
1999
California Verbal Learning Test practice effects in a schizophrenia sample
Hawkins K, Wexler B. California Verbal Learning Test practice effects in a schizophrenia sample. Schizophrenia Research 1999, 39: 73-78. PMID: 10480669, DOI: 10.1016/s0920-9964(99)00015-8.Peer-Reviewed Original ResearchConceptsPractice effectsCalifornia Verbal Learning TestVerbal Learning TestTest practice effectsLearning TestWeek 10Sample of personsNew learningSchizophrenia sampleLater performancePrior exposureNon-pharmacological interventionsSerial performanceSample of patientsClinical circumstancesWeek 14Psychiatric statusLearningSchizophreniaCVLTExact natureMemoryConsiderable retentionLarge effectExposureWill the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsBasal Ganglia DiseasesClozapineCognition DisordersHumansReaction TimeRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms
1996
Working Memory, Attention, and Communication Disturbances in Schizophrenia
Docherty N, Hawkins K, Hoffman R, Quinlan D, Rakfeldt J, Sledge W. Working Memory, Attention, and Communication Disturbances in Schizophrenia. Journal Of Psychopathology And Clinical Science 1996, 105: 212-219. PMID: 8723002, DOI: 10.1037/0021-843x.105.2.212.Peer-Reviewed Original ResearchMeSH KeywordsAdultAttentionCommunication DisordersConcept FormationFemaleHumansMaleMemory DisordersSchizophreniaSeverity of Illness IndexConceptsCommunication disturbancesConcept formationSpecific cognitive deficitsVerbal fluency testVerbal fluency test scoresWorking memoryCognitive correlatesFluency testCognitive deficitsNonpsychiatric individualsTest scoresPerformance ratingsMemoryReference performanceSchizophrenic patientsAttentionIndividualsScoresDeficitsCorrelatesSchizophreniaRatingsPerformanceImplicationsTest